Barclays PLC Taysha Gene Therapies, Inc. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Barclays PLC holds 247,280 shares of TSHA stock, worth $435,212. This represents 0.0% of its overall portfolio holdings.
Number of Shares
247,280
Previous 247,280
-0.0%
Holding current value
$435,212
Previous $513,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding TSHA
# of Institutions
117Shares Held
136MCall Options Held
25.9KPut Options Held
24K-
Avoro Capital Advisors LLC New York, NY18.7MShares$32.8 Million0.56% of portfolio
-
Rtw Investments, LP New York, NY14.9MShares$26.3 Million0.48% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$20.7 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$19.1 Million0.3% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$15.8 Million1.87% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $85.1M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...